As part of the main focus of the BDF Working Group in 2021, this document reports on the study of alternative locations and possible optimisation that may accompany the reuse of existing facilities ...with the aim of significantly reducing the costs of the facility. Building on the BDF/SHiP Comprehensive Design Study (CDS), the assessment rests on the generic requirements and constraints that allow preserving the physics reach of the facility by making use of the \(4\times 10^{19}\) protons per year at 400\,GeV that are currently not exploited at the SPS and for which no existing facility is compatible. The options considered involve the underground areas TCC4, TNC, and ECN3. Recent improvements of the BDF design at the current location (referred to as `TT90-TCC9-ECN4') are also mentioned together with ideas for yet further improvements. The assessments of the alternative locations compiled the large amount of information that is already available together with a set of conceptual studies that were performed during 2021. The document concludes with a qualitative comparison of the options, summarising the associated benefits and challenges of each option, such that a recommendation can be made about which location is to be pursued. The most critical location-specific studies required to specify the implementation and cost for each option are identified so that the detailed investigation of the retained option can be completed before the end of 2022.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces higher morbidity and mortality in hematological malignancies, but evidence in acute myeloid leukemia (AML) is scarce. A ...multicenter observational study was conducted to determine the clinical outcomes and assess the impact of therapeutic approaches in adult AML patients with SARS-CoV-2 infection in the first wave (March-May 2020). Overall, 108 patients were included: 51.9% with active leukemia and 70.4% under therapeutic schedules for AML. Signs and symptoms of SARS-CoV-2 were present in 96.3% of patients and 82.4% received specific treatment for SARS-CoV-2. The mortality rate was 43.5% and was correlated with age, gender, active leukemia, dyspnea, severe SARS-CoV-2, intensive care measures, neutrophil count, and D-dimer levels. A protective effect was found with azithromycin, lopinavir/ritonavir, and normal liver enzyme levels. During the SARS-CoV-2 first wave, our findings suggested an increased mortality in AML in a short period. SARS-CoV-2 management could be guided by risk factors in AML patients.
PDF